WeVote
Log In

Bill

Bill

SB 90

Relating to patient access to prescription drugs for off-label use.

89th Legislature (2025) Introduced by Bob Hall

SB 90 expands Texas patient access to prescription drugs for FDA-unapproved uses, potentially increasing treatment options but raising liability and safety oversight concerns.

Referred to Health & Human Services
#healthcareproviders(i0387) #health--general(i0385) #health--otherdiseases&medicalconditions(i0383) #medicalboard #texas(v0644) #medicine&prescriptiondrugs(s7338) #physicians(s1282)
0
WeVote Research Nonpartisan
Bill Summary · SB 90

Legislative bill overview

SB 90 would expand patient access to prescription drugs for off-label uses—treatments not explicitly approved by the FDA for that specific indication. The bill, introduced by Senator Bob Hall, aims to give patients and physicians greater flexibility in using existing medications for conditions beyond their original FDA approval, subject to certain safeguards.

Why is this important

Off-label drug use is already common in medical practice (estimated 20% of prescriptions), but patients sometimes face barriers accessing medications their doctors believe could help them. This bill would clarify legal protections and potentially reduce administrative obstacles, affecting both patient choice in treatment options and pharmaceutical liability considerations. The outcome could significantly impact how quickly patients gain access to potential treatments outside formal clinical trials.

Potential points of contention

  • Pharmaceutical liability: Expanding off-label use without formal FDA approval could create questions about manufacturer responsibility if adverse outcomes occur, potentially affecting insurance coverage and legal accountability
  • Medical safety standards: Critics may argue that limiting drug use to FDA-approved indications protects patients from ineffective or harmful treatments, and broader off-label access could undermine evidence-based medicine standards
  • Insurance and cost coverage: Unclear whether insurers would be required to cover off-label prescriptions, potentially shifting costs to patients or limiting practical access despite legal permission

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.